Journal article
Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics.
- Juengling FD University Bern, Medical Faculty, Bern, Switzerland.
- Allenbach G Centre hospitalier universitaire vaudois (CHUV), Lausanne, Switzerland.
- Bruehlmeier M Cantonal hospital Aarau, Aarau, Switzerland.
- Klaeser B Cantonal hospital Winterthur, Winterthur, Switzerland.
- Wissmeyer MP University hospital Zürich, Zürich, Switzerland.
- Garibotto V Hôpitaux universitaires de Genève, Geneva, Switzerland.
- Felbecker A Clinic for Neurology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
- Georgescu D Psychiatric Services Aargau, Windisch, Switzerland.
- 2020-10-20
Published in:
- Nuklearmedizin. Nuclear medicine. - 2020
English
While FDG-PET imaging of the brain for the differential diagnosis of dementia has been covered by the compulsory health insurance in Switzerland for more than a decade, beta-amyloid-PET just recently has been added to the catalogue of procedures that have been cleared for routine use, provided that a set of appropriate use criteria (AUC) be followed. To provide guidance to dementia care practitioners, the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics jointly report a mini-review on beta-amyloid-PET and discuss the AUC set into effect by the Swiss Federal Office of Public Health, as well as their application and limitations.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1055/a-1277-6014
- PMID 33080626
- Persistent URL
- https://sonar.ch/global/documents/236053
Statistics
Document views: 24
File downloads: